c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells  by Nie, Zuqin et al.
c-Myc Is a Universal Amplifier
of Expressed Genes in Lymphocytes
and Embryonic Stem Cells
Zuqin Nie,1,6 Gangqing Hu,2,6 Gang Wei,2 Kairong Cui,2 Arito Yamane,3 Wolfgang Resch,3 Ruoning Wang,4
Douglas R. Green,4 Lino Tessarollo,5 Rafael Casellas,3 Keji Zhao,2,* and David Levens1,*
1Laboratory of Pathology, NCI, Bethesda, MD, 20892, USA
2Systems Biology Center, NHLBI, Bethesda, MD 20892, USA
3Genomics and Immunity Section, NIAMS, Bethesda, MD 20892, USA
4Department of Immunology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA
5Neural Development Section, NCI, FNL, Frederick, MD 21702, USA
6These authors contributed equally to this work
*Correspondence: zhaok@nhlbi.nih.gov (K.Z.), levens@helix.nih.gov (D.L.)
http://dx.doi.org/10.1016/j.cell.2012.08.033SUMMARY
The c-Myc HLH-bZIP protein has been implicated in
physiological or pathological growth, proliferation,
apoptosis, metabolism, and differentiation at the
cellular, tissue, or organismal levels via regulation
of numerous target genes. No principle yet unifies
Myc action due partly to an incomplete inventory
and functional accounting of Myc’s targets. To
observe Myc target expression and function in a
system where Myc is temporally and physiologically
regulated, the transcriptomes and the genome-wide
distributions of Myc, RNA polymerase II, and chro-
matin modifications were compared during lympho-
cyte activation and in ES cells as well. A remarkably
simple rule emerged from this quantitative analysis:
Myc is not an on-off specifier of gene activity, but is
a nonlinear amplifier of expression, acting universally
at active genes, except for immediate early genes
that are strongly induced before Myc. This rule of
Myc action explains the vast majority of Myc biology
observed in literature.INTRODUCTION
The c-Myc oncogene, identified three decades ago, is associ-
ated with many human cancers (Dang, 2010; Wasylishen and
Penn, 2010). Numerous chromatin and transcription regulating
factors interact with Myc (Cheng et al., 1999; Cowling and
Cole, 2006; Eilers and Eisenman, 2008; Rahl et al., 2010; Wasy-
lishen and Penn, 2010). mRNA expression and DNA-binding
studies, in vitro and in vivo, have nominated an ever increasing
number of genes as Myc targets including a core constituting
a Myc signature (Ji et al., 2011; Margolin et al., 2009; Shaffer
et al., 2006; Wasylishen and Penn, 2010). However, no single
subset of Myc targets accounts for its oncogenic activity (Berns
et al., 2000; Nikiforov et al., 2002); the diversity of Myc targets68 Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc.between systems, has further confounded the explication of
discrete, linear pathway(s) for Myc-driven neoplasia.
Myc is often associated with cell activation. Typically a pulse
of Myc is induced starting from a very low baseline during
the G0–G1 transition or in response to numerous signals and
stresses (Rabbitts et al., 1985). Thereafter, in steady-state
cycling cells, c-myc output is stably maintained. In some sett-
ings, a second Myc peak ensues 12–24 hr later (Kelly et al.,
1983; Nepveu et al., 1987; Tonini et al., 1987). The relationship
between Myc targets in these primary and secondary peaks
has not been investigated. Although Myc pathology has been
extensively studied in lymphoid neoplasms, including Burkitt
lymphoma, large cell lymphoma,multiple myeloma, and plasma-
cytoma, Myc action in primary lymphocytes, has been less
studied making it difficult to compare the physiological versus
pathological Myc networks. Because most cancer lines or trans-
genic models do not recapitulate the physiologic regulation of
Myc expression (Levens, 2010), we decided to investigate Myc
function in primary lymphocytes by using a mouse line that fuses
endogenousMyc to enhanced green fluorescent protein (EGFP).
TheMyc network was then interrogated in related but physiolog-
ically distinct situations, and the profiles of global gene expres-
sion and of Myc binding to its target genes were examined.
The genome-wide patterns ofMyc recruitment, RNA polymerase
binding and chromatin modifications were overlaid to reveal the
dynamics of Myc upregulation and its relationship to lymphocyte
gene expression. These same genome-wide patterns were
assessed in ES cells to gain insight into the cell-type- and differ-
entiation-specific roles of c-Myc. Putting these data together
revealed that physiologically, Myc is not an on-off specifier of
a particular transcriptional program(s) but is a universal amplifier
of gene expression increasing output at all active promoters.
This rule predicts and explains many features of Myc biology.
RESULTS
A Model to Study Physiological Myc Function
EGFP was homologously recombined with c-myc exon 3 in
mouse ES cells (Figure S1A available online) to provide a tag
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Figure 1. Myc-EGFP Expression during Lymphocyte Activation
(A) Activation and phosphorylation of the c-Myc-EGFP knock-in. Immunoblot analysis of extract from (i) B splenocytes at 0, 1.5, 3.0, 4.5, and 6.0 hr post-LPS
activation and (ii) from ConA-activated T splenocytes at 0, 1.5, 4, 5, 8, 11, 14, and 18 hr.
(B) Flow cytometric analysis of (i) LPS-activated c-MycGFP/GFP splenic B cells at 0, 2, 4, 5, 6, and 7 hr and (ii) of ConA-activated c-MycGFP/GFP splenic T cells at 0,
1.5, 3, 4, 5, 8, 11, 14, 17, and 20 hr. The scale and axes are indicated in the left bottom corner.
See also Figure S1.for c-Myc immunoprecipitation and to monitor c-Myc levels in
living cells. This chimera preserves all known regulatory and
structural features of the endogenous c-myc gene (Liu and
Levens, 2006), including the multiple transcription and transla-
tion start sites (unlike NH2-terminal fusion [Huang et al., 2008]),
miRNA-binding sites, and 30 UTR (Ingolia et al., 2011; Liu and
Levens, 2006; Sampson et al., 2007). EGFP provided a well-
characterized and efficient tag for ChIP (Poser et al., 2008)
without compromising any surfaces that might interact with
c-Myc’s many partners (Agrawal et al., 2010).
This c-Myc-EGFP cooperated with RAS to transform cells
(Land et al., 1983) (Figure S1B) similar to the unmodified
protein and had the same short half-life (Hann and Eisenman,
1984). Crosses between mice generated from ES cells heterozy-
gous for this allele yielded unremarkable Myc-EGFP homozy-
gotes that bred without difficulty indicating that the fusion
protein functions properly from embryonic development through
adulthood.
Immunoblots of mouse embryonic fibroblasts (MEFs) wild-
type, heterozygous, or homozygous for c-Myc-EGFP probed
with anti-GFP or anti-c-Myc (Figures S1C–S1F), displayed the
expected patterns. A pulse of nuclear fluorescence occurred
when serum-starved Myc-EGFP MEFs were restimulated
(Mehmet et al., 1997); fluorescence was exaggerated upon pro-
teasome inhibitor MG132 treatment (Figures S1G and 1H). The
mean fluorescence intensity of heterozygotes at the population
and cellular levels was between that of wild-types and homozy-
gotes proving bi-allelic c-myc expression (Figure S1H).
c-Myc-EGFP Activation in Lymphocytes
To observe the interplay of Myc with the factors and pathways
activating lymphocytes, purified B or T cells were stimulatedwith lipopolysaccharide (LPS) or concanavalin A, respectively,
and monitored for EGFP-fluorescence, and total or phosphory-
lated c-Myc by immunoblotting (Figure 1). Activated B cells
displayed the stereotypical immediate-early peak of Myc (Kelly
et al., 1983) accompanied by the T58/S62 phosphorylation
(Thomas and Tansey, 2011). In T cells, c-Myc peaked biphasi-
cally 4 and 14 hr poststimulation (Kelly et al., 1983) by fluores-
cence and immunoblot; cell-cycle entry followed the second
peak. c-Myc levels were somewhat higher in the second peak;
both peaks were efficiently phosphorylated. In all respects,
c-Myc-EGFP lymphocytes functioned normally, so patterns of
gene activation and Myc target site selection were compared
in resting and stimulated B and T cells.
Quiescent B cells (B0) were treated with LPS for 4 hr (B4), and
resting T cells (T0) were activated with conA for 4 hr (T4) and for
14 hr (T14). RNA was harvested and chromatin was prepared at
these times. RNA was analyzed by hybridization with Affymetrix
microarrays, and Myc-EGFP-bound chromatin, immunoprecipi-
tated with anti-EGFP, was analyzed by ChIP-Seq. Chromatin
immunoprecipitation with antibodies against a variety of post-
translational histone modifications and RNA polymerase was
performed on quiescent and activated B cells.
Conventional Analysis Fails to Define a General
Principle for Myc Action
Because Myc regulates various synthetic and metabolic pro-
cesses, its binding was expected at genes that must be differen-
tially induced during the G0 to G1/S transition, for example
genes involved in RNA and protein biosynthesis, cell-cycle regu-
lation, and metabolism. Because the spectrum of Myc-action is
known to be complex and idiosyncratic in different systems,
strict criteria were applied in an attempt to highlight coreCell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc. 69
Myc-targets while minimizing false positives. Myc-binding sites
were assessed by using SICER and MACs (Zang et al., 2009;
Zhang et al., 2008); the former algorithm identifies broad regions
of factor binding, whereas the latter finds sharp peaks, with strin-
gent thresholds their union predicts 8020, 3053, and 6623
peaks in the B4, T4, and T14 data sets, respectively (examples
shown in Figure S2A). c-Myc peaks were enriched for E-boxes
as expected (Figure S2B). Forty to fifty percent of the Myc B
cell targets overlapped with those from an earlier study of
Burkitt’s lymphoma (Li et al., 2003) (Figure S2C). Gene ontology
of c-Myc targets revealed an amalgam of various cellular
processes (Figure S2D). A Venn diagram showed that 12%–
29% of targets were unique to a single sample, whereas the
1,045 universally shared targets constituted 13% to 34% of
each sample (Figure S2E). A global inspection of promoters
revealed that many sample-specific targets displayed sub-
threshold Myc peaks in the other samples underestimating the
number of shared targets (Figure S2F). Although largely
promoter-associated (Figure S2G), intra- and intergenic Myc-
binding sites were not rare. Microarray expression analysis of
RNA normalized between data sets, showed responsive genes
to be roughly two-thirds upregulated versus one-third downre-
gulated (Figure S2H); the magnitudes of the relative expression
changes of c-Myc target were modest (Figure S2I). Only 10%–
20% of total binding targets were upregulated and 4%–10%
were downregulated greater than 2-fold (p < 105), leaving the
importance of c-Myc binding at most genes undefined (Fig-
ure S2H). These complex patterns of binding, expression,
and function, typical for studies of this oncogene (Chen et al.,
2008; Dang, 2010; Eilers and Eisenman, 2008; Ji et al.,
2011), failed to illuminate a principle for Myc action. The dis-
cordance of targets between data sets was difficult to rationalize
in terms of cell type specificity, stage of activation or function.
In a further attempt to distill the essentials of Myc action, the
binding and expression changes among a set of genes accepted
as bona fide Myc targets were highlighted (Shaffer et al., 2006).
This Myc-signature set (defined in human cells) is comprised of
Myc-binding genes that tend to be highly expressed (Figure S3A)
and whose abundance changes with perturbation of Myc levels
in a variety of systems (Ji et al., 2011; Shaffer et al., 2006). Signa-
ture genes were highly enriched in the common sectors between
the data sets. To test whether Myc-expression is unconditionally
sufficient to enforce coherent two-fold upregulation of its signa-
ture genes, binding of Myc at their promoters was compared
between B cells activated for 4 hr versus T cells activated for 4
or 14 hr (Figure S3B). In B cells, the responsive signature genes
(37/50) were induced as a cohort at 4 hr. In contrast, the signa-
ture genes appeared to be induced biphasically in T cells
(26/50 at 4 hr increasing to 44/50 at 14 hr). No functional or onto-
logical rationale for the differential early versus late coregulation
of Myc targets in T cells was evident. Because late-activated
targets were collectively less expressed within each of the T0,
T4, and T14 data sets, the apparent late specificity might simply
reflect the kinetics at which these genes surmount arbitrary
experimental thresholds for scoring during a global ramp-up of
expression rather than precise temporal switching. Conventional
peak calling algorithms might have been biasing the identifica-
tion of Myc-target genes.70 Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc.Promoter Output Is Related to c-Myc Binding at All
Active Genes
To see if c-Myc binding related to target output without arbitrary
thresholds, all genes were binned according to expression
level, and the means of the bins were plotted against
promoter-bound c-Myc density. Remarkably, the B4, T4, and
T14 data sets each revealed a monotonic linear relationship
between the logarithm of the expression and the density of
c-Myc binding from the highest expression levels down to
background (Figure 2A); no landmark in this plot demarcated
boundaries between weak and strong c-Myc-targets. If Myc
binding is functionally proportional to the logarithm of a gene’s
expression, then perturbation of Myc levels would preferentially
disturb high-output promoters. However, the dispersion among
the data indicated that other factors modify this relationship at
the level of individual promoters (Figure S4A). To ascertain
whether the location of the bound c-Myc was one such factor,
overall expression levels were plotted against the distance of
the bound c-Myc from the TSS revealing that Myc is most
closely associated with high output if bound within 250 bp
of the TSS (Figure 2B; Figure S4B). Highly expressed Myc target
genes also tended to be associated with the Myc cognate
sequence CACGTG, the E-box, although this association was
so loose as to preclude a rigid E-box requirement (Figure S4C).
Indeed, canonical E-boxes themselves were relatively more
restricted to the vicinity of TSSs than were noncanonical
E-boxes, although both occurred frequently, as expected for
a hexanucleotide (Figure S4D). In principle, a 4/6 match to the
canonical E-box would occur every 30 nucleotides in random
50% AT/GC DNA. Empirically, even after restricting wobble to
the E-box’s central two C-G base pairs, 77% and 97% of
promoters still have E-boxes within 400 bp and 1,000 bp,
respectively, of the TSS. Degenerate E-boxes are so common
as to be essentially ubiquitous.
Myc Target Selection Is More ‘‘Analog’’ Than ‘‘Digital’’
In principle, sequence-specific transcription factor binding
occurs against a background of nonspecific binding to the rest
of the genome; so transcription factor binding sites should
resolve into two populations; a high-affinity, high-occupancy,
lower abundance population of specific binding sites versus
low-affinity, low-occupancy, but highly abundant nonspecific
binding sites comprising the bulk of the genome. In this scenario,
a histogram of the amount of transcription factor in promoter
regions would be bimodal due to nonspecific versus specific
binding as seenwith E2F1 (Figure 2C). Other factors, for example
GABP-a and CTCF may populate more complex distributions
(Figure S4E). In contrast, histograms of Myc-density were unim-
odal (Figure 2D); the absence of any local minima demarcating
low- versus high-density c-Myc binding sites renders arbitrary
any threshold selected to discriminate between these two pop-
ulations. Myc binding more resembles a continuous, analog
process, rather than the binary (digital) switch often observed
with other factors (Zhang et al., 2008). Supportive of this notion,
relaxing the stringency for peak calling using SICER returned
a much larger number of potentially significant peaks, ranging
up to 30,000–40,000 at E-value = 1,000 (Figure S2J), a threshold
where the same number of sequence tags, if randomly
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Figure 2. Myc Binds to All Promoters
According to Their Outputs
(A) Myc binding at promoters strongly correlates
with expression. Genes were sorted into 20 equal
size bins based on expression levels. The aver-
ages of Myc ChIP-Seq tag densities at promoters
and expression levels are shown for each bin.
Dashed vertical lines separate expressed genes
from silent or minimally expressed genes.
(B) Myc binding is associated with high expression
within 250 bp of the transcription start site (TSS).
Myc targets were sorted into 20 equal-size bins
based on the distance of TSS to the nearest peak
of c-Myc binding. The averages of gene expres-
sion levels (y axis) and distances (x axis) are shown
for each bin.
(C) The distribution of normalized E2F1 ChIP-Seq
tag density at mouse ES cell promoters. The y axis
shows the Gaussian kernel density for each tag
density point shown in the x axis.
(D) The distribution of normalized Myc tag density
at B4, T4, and T14 promoters.
See also Figure S4.distributed across unique sequences in the genome, would
yield 1,000 peaks. Genes bearing canonical E-boxes near
promoters populated the leading edge of this unimodal dis-
tribution but failed to separate from non-E-box Myc targets
(Figure S4F). By expression and by binding, authentic Myc-
target genes fail to resolve from the rest of the transcriptome/
genome.
If Myc mainly partitions unimodally between target sites, then
at reduced levels, Myc should populate this same distribution of
peaks but with reduced amplitude. Alternatively, if there were
several classes of Myc sites, only the highest affinity sites would
fill when Myc levels are severely restricted. In fact, ChIP-Seq for
Myc-EGFP of B0 cells that express very low levels of Myc,
revealed a proportional scaling down of all Myc peaks down
consistent with a unimodal population of binding sites paralleling
expression levels (Figure S4G).
Myc Binds to Open Chromatin
As c-Myc levels rise from baseline to high levels during lympho-
cyte activation, what features anticipate and dictate its re-
cruitment to promoters? Chromatin immunoprecipitation using
antibodies against a variety of histone modifications revealed
that Myc-binding sites in naive cells were prefigured with active
chromatin marks including H3K4Me3 and H3K27Ac (Figure 3A);
conversely, Myc was excluded from regions with repressive
histone modifications (Figure 3A). At weak binding sites, no set
of histone modifications seemed to compel Myc binding.Cell 151, 68–79, SRNAPolymerase Loading in Resting
B Cells Anticipates Myc
Recruitment after Activation
Because c-Myc binding correlated ex-
pression for all genes, we explored the
relationship between Myc recruitment
and RNA polymerase II (RNAP II) loading.
Ranking promoters in naive B cells ac-cording to the amount of RNAP II loaded, and comparing with
the amount of c-Myc subsequently recruited 4 hr postactivation,
revealed a surprising relationship: c-Myc was recruited accord-
ing to the amount of RNA polymerase preloaded at these
promoters (Figure 3B, blue). Because the gene expression
profiles of resting and activated cells are highly correlated with
each other (Figure S5) and with RNA polymerase loading, these
results indicate that c-Myc is drawn to genes already expressed
in resting cells; if so, then Myc would be a global amplifier of all
expressed genes and not a switch turning targets on or off.
Thus the association noted between c-MYC and polymerase in
lymphoma (Li et al., 2003) is found physiologically during
B cell activation and is not due toMYC overexpression in cancer.
This same relationship between TSS-bound Myc and promoter-
loaded RNA polymerase is maintained at the peak of Myc
expression during B cell activation (Figure 3B, red), indicating
that high Myc-levels do not respecify or redistribute RNA poly-
merase loading at promoters.
Myc Potentiates Pause Release at All Promoters
Myc binding at active, RNA polymerase-loaded promoters might
merely reflect access to open, actively transcribed chromatin but
lack biological significance. Or Myc recruited to TSSs might
modify the RNA polymerase profile at active promoters. Myc
has been reported to facilitate the release of RNA polymerases
paused at the promoters of its targets (Eberhardy and Farnham,
2002; Rahl et al., 2010). To test whether Myc modifies the RNAeptember 28, 2012 ª2012 Elsevier Inc. 71
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Figure 3. Myc Is Recruited to Promoters
According to the Amount of RNA Poly-
merase II Loaded
(A) Presence (red) and absence (green) of
histone markers for heterochromatin (H3K27me2/
3, H3K9me2/3, and H4K20me3) and euchromatin
(histone acetylation, H2A.Z and H3K4me3) at
naive B cell promoters. Genes are sorted by
promoter c-Myc tag density. Each line represents
a gene. Columns are hierarchically clustered. Only
chromosome 1 genes are shown.
(B) Correlation between normalized c-Myc ChIP-
Seq tag density at promoters of B4 cells and RNA
Pol II ChIP-Seq tag density at promoters of B rest-
ing cells (B0) or B4 cells, with or without 10058-F4
treatment during LPS activation. The promoters are
sorted into 20 equal-size groups based on the
c-Myc ChIP-Seq tag densities, and the averages of
the twosortsof tagdensitiesareshown for eachbin.
(C) Normalized RNA Pol II ChIP-Seq tag density
around TSS in B4 cells treated with or without
10059-F4 during B cell LPS activation.
(D) Scatter plot for RNA Pol II pausing index (Muse
et al., 2007) in B4 cells treated with and without
10058-F4.
(E) The distribution of fold-change of normalized
RNA Pol II ChIP-Seq tag density (with 10058-F4/
without 10058-F4) in promoter regions (± 2,000 bps
around TSS) and in gene body regions (excluding
the first 2,000 bps).polymerase distribution at all active genes, the Myc-Max dimer-
ization inhibitor 10058-F4 (Wang et al., 2007) was applied to cells
and the loading of polymerase at promoters and within gene
bodies was examined genome-wide. The inhibitor increased
RNA polymerase at all active promoters, commensurate with
the amount of promoter-associated Myc in uninhibited cells
(Figure 3B, red versus green and Figure 3C). There was a general
increase in the pausing index (Figure 3D), reflecting both
increased RNA polymerase at TSSs and decreased poly-
merase in gene bodies (Figure 3E), indicating that Myc is a
universal potentiator of pause-release at all actively transcribing
promoters.
Increased Myc Binding at Promoters in ES Cells Is
Associated with Increased RNA Polymerase Loading
and Higher Promoter Output
Is the universal association of c-Myc with levels of expression
and RNA polymerase II promoter loading specific to the G0-G1
transition and/or lymphocytes or is it general, occurring in other
cells and different physiological situations? To address this
issue, c-Myc binding, RNA expression, and RNA polymerase II
binding at all transcription start sites were examined in mouse
embryonic stem cells (mESCs). Again, c-Myc binding correlated
with expression (Figure 4A), and expression inversely correlated
with the distance of the Myc-binding site from the TSS (Fig-
ure 4B). The upward bow in the graph of expression (logarithm)
versus c-Myc binding (linear) for the most highly expressed
genes might suggest that these targets are beginning to saturate
(Figure 4A). As with lymphocytes (Figure 2D), the distribution of
c-Myc-density at all c-Myc peaks was unimodal (Figure 4C)
and c-Myc binding correlated with RNA polymerase II loading72 Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc.at TSSs (Figure 4D). c-Myc was recruited to promoters with
histone marks for open chromatin (Figure 4E). That the same
associations occurred in lymphocytes and mESCs suggests
that c-Myc is preferentially associated with the transcription
levels of whatever genes are on in any cell.
Myc Acts More Strongly at Promoters Than Enhancers
Because Myc binding at TSSs so closely paralleled expression,
we wondered whether this relationship extended to enhancers.
c-Myc binding was compared between p300-loaded intergenic
enhancers and their associated promoters in B4-activated
lymphocytes and in ES cells. In each case c-Myc was preferen-
tially bound at promoters (Figures 5A, 5B, 5D, and 5E). Moreover,
the RNA output of those promoters better correlated with TSS-
bound than enhancer-bound c-Myc in both systems (Figures 5C
and 5F). RNA output was especially insensitive to enhancer-
bound Myc in mESCs (Figure 5F). The data up to this point
suggest that Myc is a transcription amplifier operating at
promoters.
Myc Increases Cellular RNA Content
Is Myc an amplifier of all expressed genes? If so, then cells with
more Myc should make more of the RNAs present before Myc
upregulation. Importantly, global amplification of RNA expres-
sion would be missed in studies comparing equal amounts of
RNA versus equal cell-equivalents of RNA. Several approaches
were used to explore the relationship of Myc with total cellular
RNA and mRNA content.
First, transcriptomes were compared across a time course of
B cell activation. Despite dramatic changes in cell size (Fig-
ure S6A) and increases in mRNA and total RNA of 350% and
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Figure 4. The Association of Myc with Gene Expression, Pol II
Loading, and Open Chromatin Is Conserved in Mouse ES Cells
(A) Myc-binding levels at promoters strongly correlate with gene expression
levels (RNA-Seq). Genes were sorted into 20 equal size bins based on gene
expression level. Shown for each bin are the averages of Myc ChIP-Seq tag
densities (y axis) at promoters and of gene expression levels (x axis).
(B) Myc is associated with high gene expression if bound within 250 bp of
TSS. Data analysis as in Figure 2B.
(C) The distribution of normalized Myc tag density at promoters in mouse ES
cells.
(D) Correlation of Pol II tag densities at promoters and c-Myc ChIP-Seq tag
densities at promoters in mouse ES cells. Data analysis as in Figure 3B.
(E) Presence (red) and absence (green) of histone markers for heterochromatin
(H3K27me3, H3K9me3, and H4K20me3) and euchromatin (histone acetylation
H3K4me) at promoters from mouse ES cells. Genes are sorted by the c-Myc
tag density at promoters. Heatmap as in Figure 3A.200% per cell, respectively, by 11 hr (and up to 8.5-fold each at
48 hr; data not shown) (Figures S6B–S6D), transcriptomes were
similarly composed at all time points (Figure S5, left-most panel).
Total RNA levels in splenic B cells activated with LPS from
c-Myc-EGFP homozygous or wild-type mice were monitored
by flow cytometry using acridine orange fluorescence (James
and Eisenman, 2002). Pretreatment of LPS-activated B cells
with 10058-F4 blocked this increase in RNA (Figure 6A) but
did not affect the induction of c-Myc, an immediate early gene
(Figure 6B). Because Myc is a direct activator of the genes tran-scribed by RNA polymerases I and III (Felton-Edkins et al., 2003;
Grandori et al., 2005), as well as by RNA polymerase II,
increased rRNA was expected to account for most Myc-
elevated RNA; this was confirmed by using a BioAnalyzer
(Agilent). Estimation of non-rRNA amounts and direct measure-
ment of poly-A mRNA dramatized the rapid increase of RNA
polymerase II transcription products. It should be noted that
Myc may influence RNA levels by modulating rates of synthesis
or degradation directly or indirectly aside from controlling pause
release.
c-Myc-dependent amplification of mRNA from cells treated or
not with 10058-F4 was evaluated by qPCR of randomly chosen
mRNAs (Figure S6E) expressed at different levels and selected
without consideration of c-Myc binding. ChIP-Seq (and ChIP-
qPCR at several TSSs, not shown) using anti-EGFP confirmed
that the inhibitor globally compromised c-Myc-EGFP binding
at TSSs and enhancers (Figure 6C). Evaluation after normalizing
mRNA yield to cell number revealed that almost every mRNA
increased after B cell activation and 10058-F4 prevented these
increases (Figure 6D).
To confirm that Myc regulates total cellular RNA and mRNA
levels, c-Myc null naive B cells were recovered from mice
carrying a conditional Myc allele (Mycflox/flox) and a tamox-
ifen-inducible Cre recombinase CreERTam) (Wang et al., 2011)
that were treated with tamoxifen for 3 days. Naive splenic B cells
essentially devoid of c-Myc were activated with LPS and
analyzed for total RNA and mRNA levels as above (Wang et al.,
2011). Naive B cells from the spleens of Myc knockout mice
were smaller (Figure S7A) and contained less total RNA (Fig-
ure S7B) than their wild-type littermates. So, the small amount
ofMyc in resting cells still augments RNA levels. Upon activation,
c-Myc knockout B cells not only failed to increase the panel of
randomly selected mRNAs, total RNA, or mRNA (Figure S7C),
but the levels of these molecules actually declined, as with
10058-F4 treatment. Evidently Myc helps to maintain a cell’s
full kit. Conditional knockout of this flox/flox c-myc allele with
C19-Cre whose expression commences in pro-B cells also
yields c-Myc-less cells stuck in the early stages of activation
(de Alboran et al., 2001).
Silent and Immediate-Early Genes Are Not Myc-
Dependent
Silent genes lacking active histone marks and RNA Pol II (e.g.,
Hsd11b1 and Bex1) were unaffected by Myc inhibition (Figures
6D and 6E). The expression of several immediate early genes
(that in naive cells often reside in heterochromatin), such as
c-fos, IGF2R, BEND3 (Figure 6D), and c-Myc itself (Figure 6B),
was unperturbed by the Myc inhibitor. c-fos expression peaks
15–30 min postactivation (Figure S6F) but is already shutoff by
4 hr accompanied by H3K27-trimethylation, a marker for repres-
sive chromatin. A pulse of promoter expression that precedes
the Myc peak cannot be effectively amplified.
Several genes displayed more complex temporal pro-
files, initially rising and then falling. Acting universally during
transcription, Myc would amplify gene specific activators and
repressors that secondarily modify target expression via emer-
gent feedforward or feedback circuitry (Figure 7) and control
RNA half-life.Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc. 73
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Figure 5. Myc Prefers Promoters Over
Enhancers
(A) Distribution of Myc ChIP-Seq tag densities (B4
cells) around putative enhancers in resting B cells.
Enhancers are defined as p300-binding sites in
nonpromoter regions.
(B) Myc occupancy (B4 cells) at p300-binding sites
(resting B cells) is lower in nonpromoter versus
promoter regions.
(C) Enhancer binding correlates weakly with target
expression. The gene nearest an enhancer site is
defined as its target. p300-binding sites were
sorted by target expression levels. For each group,
the average Myc tag density near enhancers
(± 2,000 bps) is plotted versus the average target
expression level. The correlation between the
levels of Myc enhancer binding and target gene
expression was measured by Pearson Coefficient
r, in which +1 means a perfect correlation, 1
perfect negative anticorrelation, and 0 no correla-
tion. As a positive control, Myc-binding levels at
promoters of target genes are plotted against their
expression levels for each group.
(D), (E), and (F) are similar to (A), (B), (C), respec-
tively, except that the data analysis was done for
mouse ES cells.DISCUSSION
This study reports that c-Myc binding is positively correlated
with the expression levels of the vast majority of active genes
and also with Pol II binding in two primary cell types as well
as mouse ES cells. In activated B cells, Myc binding provoked
a redistribution of RNA polymerase from promoters into gene
bodies. The simplest interpretation of all these results is that
c-Myc is a universal amplifier of transcription that drives the
transcription machinery through pause release. The discor-
dance of Myc targets between cell types, and the concordance
of expressed genes irrespective of Myc levelswithin a single cell
type, dictates that Myc is neither a specifier nor reprogrammer
of cell fate. Most simply, c-Myc is a universal amplifier of
expression. Total RNA levels, not just differential expression,
must be compared between samples to appreciate this effect.
Some genes may be exempted from Myc amplification via
c-Myc-interacting repressors such Miz-1(Herkert and Eilers,
2010) or via negative feedback through Myc induced repressors
(Liu and Levens, 2006). Whether Myc primarily upregulates
targets via PTEF-b stimulated release of promoter paused
RNAPII (Rahl et al., 2010), or exploits additional mechanisms
(Cheng et al., 1999; Cowling and Cole, 2006; Eilers and Eisen-
man, 2008; Rahl et al., 2010; Wasylishen and Penn, 2010)
may depend on whether all promoters follow a universal reac-
tion scheme. If different promoters are limited at several distinct
or multiple kinetically equivalent steps, then a universal activator
such as Myc, must be a molecular Swiss Army knife functioning
at different steps (Figure 7, right) to generate kinetic synergy
(Chung and Levens, 2005; Herschlag and Johnson, 1993), ratio-
nalizing the plethora of activities marshaled by c-Myc (Cowling
and Cole, 2006). If recruited Myc stimulates pause-release and
facilitates promoter reloading, then it would operate preferen-
tially at highly expressed genes, perhaps enhancing their74 Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc.nonlinear preferential amplification. c-Myc also activates RNA
polymerases I and III, rRNA transcribed by the former account-
ing for the bulk of the RNA (James and Eisenman, 2002).
c-Myc also directly augments DNA replication (Dominguez-
Sola et al., 2007). Considering Myc to be a universal amplifier
may help to explain and predict its role in diverse biological
systems.
Metabolism and Cell Size
Upregulating all active genes, c-Myc increases the flux through
cellular networks (Figure 7). In an anabolic cell, such increased
throughput would drive cell growth yielding bigger cells. To
tune the expression of specific genes, specific regulation must
be superimposed over this global upregulation as described
for densely overlapping regulons (Alon, 2007). Although the net
output of many pathways would scale linearly andmonotonically
as the synthesis of their components increases, other processes
are inherently nonlinear and would respond according to thresh-
olds wired into their pathways (Figure 7).
Proliferation and Apoptosis
The differential responses of different pathways to changes in
Myc abundance do not demand differential upregulation of their
components. For example, cell division is all-or-none. Until cell-
cycle components exceed a mitogenic threshold, amplification
by Myc is irrelevant. Myc amplification is also irrelevant if prolif-
eration genes are off when Myc is expressed, explaining why
enforcedMyc expression is tumorigenic in growing or regenerat-
ing but not adult mouse livers (Beer et al., 2004). Similarly, upre-
gulating the apoptosis apparatus across critical thresholds
eventually triggers cell death. Adjustments in the settings for
such critical thresholds depend on the inventory of regulatory
factors in any given cell; the composition of this inventory is
largely not under Myc’s purview.
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Figure 6. c-Myc Amplifies All Expressed Genes in B Splenocytes (see also Figure S7)
(A) and (B) Flow cytometric analysis of total acridine orange (AO) stained RNA (A) and c-Myc-EGFP (B) in LPS-activated B splenocytes at 0, 4, 8, and 11 hr. The
cells from wild-type (yellow) or c-Myc -EGFP mice were treated with (red), or without (blue) Myc-Max inhibitor 10058-F4. The error bars represent the SD (n = 3).
(C) Heatmap of c-Myc tag density (against IgG) near TSS (±2,000 bps; 40 windows) for LPS-activated B4 cells treated with and without 10058-F4. Genes are
sorted into 100 equal size bins based on expression levels. Shown are the averaged c-Myc tag densities for each bin. The analysis was repeated for p300 binding
sites pre-established in resting B cells in nonpromoter regions, serving as a proxy for enhancers. The p300 binding sites are sorted into 100 bins based on the
H3k27ac level, an estimate of enhancer activity (Creyghton et al., 2010; Rada-Iglesias et al., 2011)).
(D) Q-RT-PCR analysis of genes selected randomly from expression array data. Cells were cultured with or without 10058-F4. Two immediate-early genes,Bend3
and Igf2R, expressed with or before c-Myc were 10058-F4 insensitive. Genes Hsd11b1 and Bex1 reside in heterochromatin and are inactive. The error bars
represent the SD (n = 3).
(E) The heterochromatin versus euchromatin features of Traf3ip3 and Myc-insensitive genes (Hsd11b1 and Bex1).
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Figure 7. Myc Controls Cellular Subnetworks by Transcriptionally Varying Their Component Concentrations
Left–Global upregulation of MYC provokes linear and nonlinear changes in outputs of cellular subsystems according to network architecture. By
inducing activators and repressors, a panoply of feedback and coherent and incoherent feedforward loops are employed according to programs pre-existing in
the cells. Right—Myc’s multiple partners have the potential to expedite passage through multiple stages of the transcription cycle and to create kinetic synergy
(Chung and Levens, 2005; Herschlag and Johnson, 1993). Myc stimulated pause release and promoter reloading would amplify expression according to output
levels.Sustained Myc Expression and Implications for Cancer
Physiologically, c-Myc is usually expressed as an immediate
early pulse before returning to baseline. Such a pulse would drive
the accumulation of themacromolecules needed for proliferation
or other preprogrammed pathways; without Myc these path-
ways would labor as cells gradually ramped up their synthetic
capacity. ThusMycwould provide a bolus of material supporting
all pathways until control is assumed by dedicated regulatory
factors. Sustained Myc overexpression in cancer would leave
cells in a state of chronic overdrive through all cellular networks.
At pathological levels, when Myc invades enhancers, many
cellular subsystems may be driven across critical thresholds
(Lin et al., 2012). Under these circumstances, even a modest
reduction in Myc may be sufficient to deprive cells of the net
anabolic, metabolic and mitogenic impulse necessary to sustain
unchecked proliferation.
Myc maybe pathologically upregulated by a host of mecha-
nisms such as chromosomal rearrangements or unchecked
stimulation directing transcription factors to the c-myc regula-
tory sequences that serve as an antenna for signals from
many cellular subsystems. Because amplification of the factors
driving Myc would create a dangerous positive feedback loop,
Myc must also induce repressors to limit its own synthesis (Lev-
ens, 2010; Liu and Levens, 2006; Wierstra and Alves, 2008);
abrogation of this negative feedback would also enforce Myc
overexpression. Mutations that increase Myc levels and over-
drive the apoptotic machinery must be balanced by the over-
production of survival factors. Weaning cells from high Myc
levels could potentially create an imbalance between longer-
lived proapoptotic and shorter-lived antiapoptotic factors
(Sharma et al., 2006) and contribute to oncogene addiction
by Myc.76 Cell 151, 68–79, September 28, 2012 ª2012 Elsevier Inc.Differentiation
c-Myc expression almost always declines, at least transiently
during differentiation when large batteries of genes must be
turned on and off to enable reprogramming. As an amplifier,
Myc would reinforce whatever state a cell is in. Suspending
Myc-driven amplification would enable more efficient and rapid
reprogramming. Thereafter increasedMyc levels would reinforce
the new cell state. Exactly such differentiation-linked biphasic
Myc expression has beendescribed in severalmodels of erythro-
leukemia cells (Dmitrovsky et al., 1986; Nepveu et al., 1987;
Tonini et al., 1987). In EScells, highMyc levels reinforce the undif-
ferentiated state to prevent stochastic differentiation. During the
generation of iPS cells, Myc may help to trap genes in the on-
state as they are transiently activated by reprogramming factors.
What about Myc Repressed Genes?
If Myc is a universal amplifier of gene activation, why do previous
studies estimate1/3 of Myc targets to be downregulated? Two
reasons may explain repression by Myc. First, when comparing
RNA expression between samples normalized for equal amounts
of RNA (versus equal numbers of cells), ‘‘repressed’’ genes may
actually be upregulated by Myc at the cellular level, just less so
than the average gene. Second, repression may be indirect as
transcriptional or chromatin repressors activated by Myc are
recruited to Myc target genes. For example during B cell activa-
tion, c-Myc bound and upregulated the EZH2 promoter (Fig-
ure 6D); EZH2 mediates transcriptional repression across the
genome by catalyzing methylation of histone H3 lysine 27. Myc
also induces a number of miRNAs that limit the amplification of
their targets (Bui and Mendell, 2010).
In summary, Myc is a universal of amplifier of gene activa-
tion; to predict precisely the response of cells and tissues to
physiological, pathological, or therapeutic manipulation of Myc,
it will be necessary to elucidate how Myc-amplification changes
the flux through cellular compartments and subnetworks to
determine cell fate in health and disease.
EXPERIMENTAL PROCEDURES
Isolation and Activation of Mouse Splenocytes
Naive mouse B or T splenocytes from 8–11 week mice were negatively
selected with CD-43-(Ly48) MicroBeads (MACS, Miltenyi Biotech, Cat. no.
130-049-801) or Pan T cell isolation kit (MACS, Cat. no. 130-095-130),
respectively. Isolated splenocytes were cultured at 0.5 3 106 cells/ml in
RPMI 1640 (GIBCO-Invitrogen) with HEPES, L-glutamine, sodium pyruvate,
and 50mM b-mercaptoethanol. B cells were activated with lipopolysaccharide
(LPS, 25 mg/ml) (SIGMA) for different times. For Myc inhibition, cells were
treated with 66.5 mM 10058-F4 (SIGMA) for 2 hr before LPS stimulation.
T-splenocytes were cultured at 13 106 cells/ml in the samemedium as B cells
and activated with Concanavalin A (ConA, 7.5 mg/ml) (SIGMA) for different
times.
Antibodies
Full length A.V. polyclonal anti-GFP (Clontech, 632460) was used for mouse
B cell ChIP analysis, MEF immunoprecipitation, and blot analysis. Anti-Myc
(Santa Cruz, SC-41, C-8) was also used for the MEF immunoprecipitation
and blot analysis. Normal mouse IgG (Santa Cruz SC-2025) and normal rabbit
IgG (Santa Cruz SC-2027) were used for the ChIP control. Anti-RNA poly-
merase II CTD repeat YSPTSPS [4H8] - ChIP Grade (ab5408) was used for
the Pol II ChIP analysis.
c-Myc (N-term) antibody (Epitomics, 1472-1) and c-Myc Phospho (pT58/
pS62) antibody (Epitomics, 1203-1) were used for immunoblot analysis of
c-Myc expression and phosphorylation in B and T cells, respectively. The anti-
bodies for histone modifications were described previously (Kuchen et al.,
2010; Yamane et al., 2011).
Flow Cytometry
Steady state, serum-starved and restimulated MEFs; propidium-iodide-
stained naive, LPS or ConA stimulated splenocytes; or acridine orange (AO)
stained B cells were analyzed by flow cytometry to detect c-Myc-EGFP and/
or RNA intensity (AO) on Cyflow ML Instrument (PARTEC) by using FloMAX
and/or FlowJo (Treestar version 7.6.1) software. At least 25,000 events were
acquired for each sample.
ChIP-Seq and Expression Arrays
Chromatin immunoprecipitation and sequencing (ChIP-Seq) were performed
as described (Barski et al., 2007). ChIP-Seq data sets for histone modifica-
tions H3K4me1, H3K27me3, H4K20me3, and H3K9me3 and ChIP-Seq data
sets for TFs c-Myc and E2F1 in mouse ES cells were from Mikkelsen et al.
(2007) and Chen et al. (2008), respectively. RNA-Seq library preparation
and sequencing for mouse ES cells followed the procedure described in
Chepelev et al. (2009). Sequence reads of 25 bp for ChIP-Seq and 36 bp
for RNA-Seq were generated from an Illumina Genome Analyzer, mapped
to mouse genome (mm8) by using Bowtie (Langmead et al., 2009). ChIP-
Seq-tag-enriched regions were predicted by SICER (Zang et al., 2009) and
MACS(Zhang et al., 2008). Heatmaps relating histone modification to Myc
ChIP-Seq tag density were performed by MeV (Chu et al., 2008). The
mRNA expression level of UCSC known genes was quantified by the RPKM
measure from RNA-Seq data set (read per kilobase of exon model per million
reads) based on UCSC known genes annotations.
Total RNAs were isolated from B or T splenocytes with TRIzol Reagent
(Invitrogen) and analyzed by using Affymetrix expression arrays. RNA quality
was checked on Agilent Bioanalyzer. All microarray samples had a high quality
score (RIN > 9). RNA (100 ng) was reverse transcribed and labeled with biotin
using Affymetrix 30 IVTexpress Labeling according to the manufacturer’s
protocol. Four biological replicates of each group were labeled, and hybrid-
ized to Affymetrix mouse 430 2.0 GeneChip and scanned on Affymetrix
GeneChip scanner 3000. Data were collected using Affymetrix AGCC soft-ware. Quantification of mRNA expression levels, GCRMA normalization, and
call of differentially expressed genes used affylmGUI software (Wettenhall
et al., 2006).
Q-RT-PCR Analysis of the Expression of Random Selected Genes
Total RNAswere purified from resting LPS-stimulated and 10058-F4-treated B
splenocytes at various time points; 0.25 mg of total RNA from each sample
programmed first-strand c-DNA synthesis using Enhanced Avian HS RT-
PCR-100 kit (SIGMA, Cat. No. HSRT100-1kt). The primers and probes for
each gene were designed using Roche Universal Probelibrary Assay Design
Center Web (Figure S7F). q-PCRs were performed with Roche LightCycler
480 system (LightCycler 480 ProbeMaster, Ref. No. 04 707 494 001; Universal
Probelibrary set, Human, Ref. No. 04 683 633 001). The gene expression levels
were adjusted according to the cell number used for input RNA, normalized to
the RNA level of an untreated resting cell.ACCESSION NUMBERS
The GEO accession number for the microarray and ChIP-Seq data reported in
this paper is GSE37230.SUPPLEMENTAL INFORMATION
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